Hongxia Zhao, Guang Zhu, Tong Zhu, Binbin Ding, Ahong Xu, Songyan Gao, Yufan Chao, Na Li, Yongchun Chen, Zuowei Wang, Yong Jie, Xin Dong
BACKGROUND: Schizophrenia (SCZ) patients undergoing antipsychotic treatment demonstrated a high prevalence and harmful effects of metabolic syndrome (MetS), which acted as the major cause of cardiovascular disease. The major clinical challenge is the lack of biomarkers to identify MetS episodes and prevent further damage, while the mechanisms underlying these drug-induced MetS remain unknown. METHODS: This study divided 173 participants with SCZ into 3 groups (None, High risk, and MetS, consisting of 22, 88, and 63 participants, respectively)...
July 24, 2024: BMC Psychiatry